A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple Myeloma

Inclusion Criteria:

1. Man or woman aged 18 to 65 years old;
2. Subjects are newly diagnosed MM patients which are scheduled by the investigators to be treated with vincristine, adriamycin and dexamethasone standard therapy. Stage II/III (according to Durie and Salmon criteria) with skeletal involvement, such as bone pain, bone lytic lesions, diffuse osteoporosis or pathologic fractures;
3. Life expectancy \> 3 months;
4. Patient has measurable disease in which to capture response, defined as one or more of the following;

   * Serum M-protein level \>10.0 g/L measured by serum protein electrophoresis or immunoglobulin electrophoresis; or
   * Urinary M-protein excretion \> 1 g/24 hours; or
   * Bone marrow plasmacytosis of \> 30% by bone marrow aspirate and/or biopsy; or
   * Serum free light chains (by the Freelite test) \> 2 X the upper limit of normal (ULN), in the absence of renal failure.
5. Performance status (PS) of ECOG ≤2.0, unless PS of 3-4 based solely on bone pain;
6. Patients must have a Platelets count≥50×109 cells /L; Absolute neutrophil count (ANC)≥0.75×109 cells /L;
7. Patients must have adequate hepatic function defined as Alanine transaminase(ALT) ≤ 2.5 × upper limit of normal(ULN); Aspartate transaminase (AST) ≤2.5×ULN; Total bilirubin ≤2×ULN;
8. Patients must have adequate renal function defined as creatinine clearance \>30 ml /min;
9. Subjects (or their legally acceptable representatives) must have signed a informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.

Exclusion Criteria:

1. Non-secretory MM, unless the patient has measurable lesions on computed tomography (CT), magnetic resonance imaging (MRI) and/or positron emission tomography (PET);
2. Peripheral neuropathy or neuropathy pain grade 2 or high as defined by National Cancer Institute Common Terminology Criteria for Adverse Events(NCI CTCAE) Version 3;
3. Uncontrolled or severe cardiovascular disease, including myocardial infarction (MI ) within 6 months of enrollment, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis;
4. History of allergy reaction attributable to compounds containing boron or mannitol;
5. Any serious, active disease or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol or the investigator's decision;
6. Concurrent treatment with another investigational agent;
7. Female subject who is pregnant or breast-feeding.